Glucagon-Like Peptide-1 Receptors in the Kidney: Impact on renal autoregulation

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

Glucagon-Like Peptide-1 Receptors in the Kidney : Impact on renal autoregulation. / Hviid, Aleksander V R; Sorensen, Charlotte M.

I: American Journal of Physiology: Renal Physiology, Bind 318, Nr. 2, 2020, s. F443-F454.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Hviid, AVR & Sorensen, CM 2020, 'Glucagon-Like Peptide-1 Receptors in the Kidney: Impact on renal autoregulation', American Journal of Physiology: Renal Physiology, bind 318, nr. 2, s. F443-F454. https://doi.org/10.1152/ajprenal.00280.2019

APA

Hviid, A. V. R., & Sorensen, C. M. (2020). Glucagon-Like Peptide-1 Receptors in the Kidney: Impact on renal autoregulation. American Journal of Physiology: Renal Physiology, 318(2), F443-F454. https://doi.org/10.1152/ajprenal.00280.2019

Vancouver

Hviid AVR, Sorensen CM. Glucagon-Like Peptide-1 Receptors in the Kidney: Impact on renal autoregulation. American Journal of Physiology: Renal Physiology. 2020;318(2):F443-F454. https://doi.org/10.1152/ajprenal.00280.2019

Author

Hviid, Aleksander V R ; Sorensen, Charlotte M. / Glucagon-Like Peptide-1 Receptors in the Kidney : Impact on renal autoregulation. I: American Journal of Physiology: Renal Physiology. 2020 ; Bind 318, Nr. 2. s. F443-F454.

Bibtex

@article{5ce9af130bbe4a278cbfa5c3ff1cefdf,
title = "Glucagon-Like Peptide-1 Receptors in the Kidney: Impact on renal autoregulation",
abstract = "Glucagon-like peptide-1 (GLP-1) and strategies based on this blood sugar-reducing and appetite-suppressing hormone are used to treat obesity and type-2 diabetes. However, the GLP-1 receptor (GLP-1R) is also present in the kidney where it influences renal function. The effect of GLP-1 on the kidney varies between humans and rodents. The effect of GLP-1 on kidney function also seems to vary depending on its concentration and the physiological or pathological state of the kidney. In studies with rodents or humans, acute infusion of pharmacological doses of GLP-1 stimulates natriuresis and diuresis. However, the effect on the renal vasculature is less clear. In rodents, GLP-1 infusion increases renal plasma flow (RPF) and glomerular filtration rate (GFR), suggesting renal vasodilation. In humans, only a subset of the subjects exhibits increased RPF and GFR. Differential status of kidney function and changes renal vascular resistance of the preglomerular arterioles, may account for the different responses of the human subjects. Because renal function in type-2 diabetic patients is already at risk or compromised, understanding the effects of GLP-1R activation on kidney function in these patients is particularly important. This review examines the distribution of GLP-1R in the kidney and the effects elicited by GLP-1 or GLP-1R agonists. By integrating results from acute and chronic studies in healthy individuals and type-2 diabetic patients along with those from rodent studies, we provide insight into how GLP-1R activation affects renal function and autoregulation.",
author = "Hviid, {Aleksander V R} and Sorensen, {Charlotte M}",
year = "2020",
doi = "10.1152/ajprenal.00280.2019",
language = "English",
volume = "318",
pages = "F443--F454",
journal = "American Journal of Physiology: Renal Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "2",

}

RIS

TY - JOUR

T1 - Glucagon-Like Peptide-1 Receptors in the Kidney

T2 - Impact on renal autoregulation

AU - Hviid, Aleksander V R

AU - Sorensen, Charlotte M

PY - 2020

Y1 - 2020

N2 - Glucagon-like peptide-1 (GLP-1) and strategies based on this blood sugar-reducing and appetite-suppressing hormone are used to treat obesity and type-2 diabetes. However, the GLP-1 receptor (GLP-1R) is also present in the kidney where it influences renal function. The effect of GLP-1 on the kidney varies between humans and rodents. The effect of GLP-1 on kidney function also seems to vary depending on its concentration and the physiological or pathological state of the kidney. In studies with rodents or humans, acute infusion of pharmacological doses of GLP-1 stimulates natriuresis and diuresis. However, the effect on the renal vasculature is less clear. In rodents, GLP-1 infusion increases renal plasma flow (RPF) and glomerular filtration rate (GFR), suggesting renal vasodilation. In humans, only a subset of the subjects exhibits increased RPF and GFR. Differential status of kidney function and changes renal vascular resistance of the preglomerular arterioles, may account for the different responses of the human subjects. Because renal function in type-2 diabetic patients is already at risk or compromised, understanding the effects of GLP-1R activation on kidney function in these patients is particularly important. This review examines the distribution of GLP-1R in the kidney and the effects elicited by GLP-1 or GLP-1R agonists. By integrating results from acute and chronic studies in healthy individuals and type-2 diabetic patients along with those from rodent studies, we provide insight into how GLP-1R activation affects renal function and autoregulation.

AB - Glucagon-like peptide-1 (GLP-1) and strategies based on this blood sugar-reducing and appetite-suppressing hormone are used to treat obesity and type-2 diabetes. However, the GLP-1 receptor (GLP-1R) is also present in the kidney where it influences renal function. The effect of GLP-1 on the kidney varies between humans and rodents. The effect of GLP-1 on kidney function also seems to vary depending on its concentration and the physiological or pathological state of the kidney. In studies with rodents or humans, acute infusion of pharmacological doses of GLP-1 stimulates natriuresis and diuresis. However, the effect on the renal vasculature is less clear. In rodents, GLP-1 infusion increases renal plasma flow (RPF) and glomerular filtration rate (GFR), suggesting renal vasodilation. In humans, only a subset of the subjects exhibits increased RPF and GFR. Differential status of kidney function and changes renal vascular resistance of the preglomerular arterioles, may account for the different responses of the human subjects. Because renal function in type-2 diabetic patients is already at risk or compromised, understanding the effects of GLP-1R activation on kidney function in these patients is particularly important. This review examines the distribution of GLP-1R in the kidney and the effects elicited by GLP-1 or GLP-1R agonists. By integrating results from acute and chronic studies in healthy individuals and type-2 diabetic patients along with those from rodent studies, we provide insight into how GLP-1R activation affects renal function and autoregulation.

U2 - 10.1152/ajprenal.00280.2019

DO - 10.1152/ajprenal.00280.2019

M3 - Review

C2 - 31841385

VL - 318

SP - F443-F454

JO - American Journal of Physiology: Renal Physiology

JF - American Journal of Physiology: Renal Physiology

SN - 1931-857X

IS - 2

ER -

ID: 232063033